Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The rat parvovirus H-1 (H-1PV) attracts high attention as an anticancer agent, because it is not pathogenic for humans and has oncotropic and oncosuppressive properties. The viral nonstructural NS1 protein is thought to mediate H-1PV cytotoxicity, but its exact contribution to this process remains undefined. In this study, we analyzed the effects of the H-1PV NS1 protein on human cell proliferation and cell viability. We show that NS1 expression is sufficient to induce the accumulation of cells in G(2) phase, apoptosis via caspase 9 and 3 activation, and cell lysis. Similarly, cells infected with wild-type H-1PV arrest in G(2) phase and undergo apoptosis. Furthermore, we also show that both expression of NS1 and H-1PV infection lead to higher levels of intracellular reactive oxygen species (ROS), associated with DNA double-strand breaks. Antioxidant treatment reduces ROS levels and strongly decreases NS1- and virus-induced DNA damage, cell cycle arrest, and apoptosis, indicating that NS1-induced ROS are important mediators of H-1PV cytotoxicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876649PMC
http://dx.doi.org/10.1128/JVI.01797-09DOI Listing

Publication Analysis

Top Keywords

parvovirus h-1
8
reactive oxygen
8
oxygen species
8
ns1 protein
8
h-1pv cytotoxicity
8
h-1pv
6
ns1
5
nonstructural protein
4
protein ns1
4
ns1 parvovirus
4

Similar Publications

Unlabelled: Oncolytic protoparvoviruses, including LuIII, H-1 parvovirus (H-1PV), and the prototypic strain of minute virus of mice (MVMp), can target and destroy cancer cells. Host cell targeting is based largely on the identification and interaction of the virus with the primary receptor. Previously, it has been shown that MVMp and H-1PV bind to sialic acid (SIA), which is the primary glycan receptor.

View Article and Find Full Text PDF
Article Synopsis
  • The rat protoparvovirus H-1 (H-1PV) is known for its anticancer effects in human tumors, particularly non-Hodgkin lymphomas (NHL), but its impact on T-cell malignancies has been less studied.
  • A pilot study showed that H-1PV successfully infected and induced cancer cell death in cutaneous T-cell lymphoma (CTCL) models, while not affecting healthy cells, and even increased immune cell infiltration in cancer spheroids.
  • The findings suggest that H-1PV could be a promising new treatment option for CTCL, highlighting its potential as a viroimmunotherapeutic candidate.
View Article and Find Full Text PDF

Cutaneous T-cell lymphoma (CTCL) is a devastating, potentially fatal T-lymphocyte malignancy affecting the skin. Despite all efforts, the etiology of this disease remains unknown. Infectious agents have long been suspected as factors or co-factors in CTCL pathogenesis.

View Article and Find Full Text PDF

The oncolytic rodent protoparvovirus H-1PV has been successfully used in phase I/II clinical trials to treat recurrent glioblastoma multiforme and pancreatic cancer. The present work focuses on the stability and environmental safety of the H-1PV drug product from production up to its use in patients. We identified hold-steps in manufacturing for up to 3 months and showed 7-years stability for the optimal product formulation.

View Article and Find Full Text PDF

The oncolytic rodent protoparvoviruses (PVs) minute virus of mice (MVMp) and H-1 parvovirus (H-1PV) are promising cancer viro-immunotherapy candidates capable of both exhibiting direct oncolytic activities and inducing anticancer immune responses (AIRs). Type-I interferon (IFN) production is instrumental for the activation of an efficient AIR. The present study aims at characterizing the molecular mechanisms underlying PV modulation of IFN induction in host cells.

View Article and Find Full Text PDF